Genmab launches “AI Everywhere”

Genmab isn't exactly a household name, but inside the world of cancer therapeutics it's a serious player, the kind of company whose research pipelines involve years of clinical trial data, regulatory filings, and intellectual property that absolutely cannot leak. So when a biotech like this decides to put ChatGPT Enterprise in front of every employee, the story isn't really about chatbots writing emails faster. It's about what it took to get a company this cautious to say yes.

The program, branded internally as "AI Everywhere," is Genmab's attempt to normalize AI use across departments rather than confining it to a data science team or an innovation lab that nobody else touches. That's a different bet than most enterprise AI rollouts, which tend to start narrow and expand slowly. Genmab is going wide first, betting that broad familiarity beats narrow expertise when the tool is meant to become part of daily workflow rather than a novelty.

What makes this possible, according to OpenAI's own framing, is the enterprise tier's separation from the consumer product. No training on customer data, encryption commitments, compliance certifications, admin-level control over usage — the standard checklist that any pharma legal team demands before letting employees near a general-purpose chatbot. For a company operating under FDA and EMA scrutiny, those guardrails aren't a nice-to-have; they're the whole reason the deal exists.

There's also a quieter signal here about where OpenAI wants to plant its flag next. Life sciences companies have been slower than banks or law firms to embrace generalist AI tools, partly because the cost of a data mistake is measured in clinical trial delays, not just embarrassment. Landing a biotech willing to talk publicly about enterprise-wide adoption gives OpenAI a case study it can wave at every other cautious regulated industry watching from the sidelines.